Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections

Monica A. Donnelley, Elizabeth S. Zhu, George Richard Thompson

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

We have a limited arsenal with which to treat invasive fungal infections caused by Aspergillus and Mucorales. The morbidity and mortality for both pathogens remains high. A triazole antifungal, isavuconazole, was recently granted approval by the US Food and Drug Administration and the European Medicines Agency for the treatment of invasive aspergillosis and mucormycosis. A randomized double-blind comparison trial for the treatment of invasive aspergillosis found isavuconazole noninferior to voriconazole. A separate, open-label study evaluating the efficacy of isavuconazole in the treatment of mucormycosis found comparable response rates to amphotericin B and posaconazole treated historical controls. The prodrug isavuconazonium sulfate is commercially available in both an oral and intravenous formulation and is generally well tolerated. Isavuconazole’s broad spectrum of activity, limited side effect profile, and favorable pharmacokinetics will likely solidify its place in therapy.

Original languageEnglish (US)
Pages (from-to)79-86
Number of pages8
JournalInfection and Drug Resistance
Volume9
DOIs
StatePublished - Jun 2 2016

Fingerprint

Mucormycosis
Aspergillosis
Infection
Mucorales
Triazoles
Prodrugs
Amphotericin B
United States Food and Drug Administration
Aspergillus
Pharmacokinetics
isavuconazole
Morbidity
Mortality

Keywords

  • Antifungal
  • Clinical efficacy
  • Isavuconazonium
  • Mold infection
  • Mucor
  • New agent
  • Pharmacodynamics
  • Pharmacokinetics
  • Therapy
  • Zygomycosis

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Pharmacology

Cite this

Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections. / Donnelley, Monica A.; Zhu, Elizabeth S.; Thompson, George Richard.

In: Infection and Drug Resistance, Vol. 9, 02.06.2016, p. 79-86.

Research output: Contribution to journalReview article

@article{89c44b2abffc4f20b75b6e756b4d0d46,
title = "Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections",
abstract = "We have a limited arsenal with which to treat invasive fungal infections caused by Aspergillus and Mucorales. The morbidity and mortality for both pathogens remains high. A triazole antifungal, isavuconazole, was recently granted approval by the US Food and Drug Administration and the European Medicines Agency for the treatment of invasive aspergillosis and mucormycosis. A randomized double-blind comparison trial for the treatment of invasive aspergillosis found isavuconazole noninferior to voriconazole. A separate, open-label study evaluating the efficacy of isavuconazole in the treatment of mucormycosis found comparable response rates to amphotericin B and posaconazole treated historical controls. The prodrug isavuconazonium sulfate is commercially available in both an oral and intravenous formulation and is generally well tolerated. Isavuconazole’s broad spectrum of activity, limited side effect profile, and favorable pharmacokinetics will likely solidify its place in therapy.",
keywords = "Antifungal, Clinical efficacy, Isavuconazonium, Mold infection, Mucor, New agent, Pharmacodynamics, Pharmacokinetics, Therapy, Zygomycosis",
author = "Donnelley, {Monica A.} and Zhu, {Elizabeth S.} and Thompson, {George Richard}",
year = "2016",
month = "6",
day = "2",
doi = "10.2147/IDR.S81416",
language = "English (US)",
volume = "9",
pages = "79--86",
journal = "Infection and Drug Resistance",
issn = "1178-6973",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections

AU - Donnelley, Monica A.

AU - Zhu, Elizabeth S.

AU - Thompson, George Richard

PY - 2016/6/2

Y1 - 2016/6/2

N2 - We have a limited arsenal with which to treat invasive fungal infections caused by Aspergillus and Mucorales. The morbidity and mortality for both pathogens remains high. A triazole antifungal, isavuconazole, was recently granted approval by the US Food and Drug Administration and the European Medicines Agency for the treatment of invasive aspergillosis and mucormycosis. A randomized double-blind comparison trial for the treatment of invasive aspergillosis found isavuconazole noninferior to voriconazole. A separate, open-label study evaluating the efficacy of isavuconazole in the treatment of mucormycosis found comparable response rates to amphotericin B and posaconazole treated historical controls. The prodrug isavuconazonium sulfate is commercially available in both an oral and intravenous formulation and is generally well tolerated. Isavuconazole’s broad spectrum of activity, limited side effect profile, and favorable pharmacokinetics will likely solidify its place in therapy.

AB - We have a limited arsenal with which to treat invasive fungal infections caused by Aspergillus and Mucorales. The morbidity and mortality for both pathogens remains high. A triazole antifungal, isavuconazole, was recently granted approval by the US Food and Drug Administration and the European Medicines Agency for the treatment of invasive aspergillosis and mucormycosis. A randomized double-blind comparison trial for the treatment of invasive aspergillosis found isavuconazole noninferior to voriconazole. A separate, open-label study evaluating the efficacy of isavuconazole in the treatment of mucormycosis found comparable response rates to amphotericin B and posaconazole treated historical controls. The prodrug isavuconazonium sulfate is commercially available in both an oral and intravenous formulation and is generally well tolerated. Isavuconazole’s broad spectrum of activity, limited side effect profile, and favorable pharmacokinetics will likely solidify its place in therapy.

KW - Antifungal

KW - Clinical efficacy

KW - Isavuconazonium

KW - Mold infection

KW - Mucor

KW - New agent

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Therapy

KW - Zygomycosis

UR - http://www.scopus.com/inward/record.url?scp=84973460227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973460227&partnerID=8YFLogxK

U2 - 10.2147/IDR.S81416

DO - 10.2147/IDR.S81416

M3 - Review article

VL - 9

SP - 79

EP - 86

JO - Infection and Drug Resistance

JF - Infection and Drug Resistance

SN - 1178-6973

ER -